{"doi":"10.1002/adhm.202400249","title":"Conjugation of IL‐33 to Microporous Annealed Particle Scaffolds Enhances Type 2‐Like Immune Responses In Vitro and In Vivo","abstract":"The inflammatory foreign body response (FBR) is the main driver of biomaterial implant failure. Current strategies to mitigate the onset of a FBR include modification of the implant surface, release of anti-inflammatory drugs, and cell-scale implant porosity. The microporous annealed particle (MAP) scaffold platform is an injectable, porous biomaterial composed of individual microgels, which are annealed in situ to provide a structurally stable scaffold with cell-scale microporosity. MAP scaffold does not induce a discernible foreign body response in vivo and, therefore, can be used a \"blank canvas\" for biomaterial-mediated immunomodulation. Damage associated molecular patterns (DAMPs), such as IL-33, are potent regulators of type 2 immunity that play an important role in tissue repair. In this manuscript, IL-33 is conjugated to the microgel building-blocks of MAP scaffold to generate a bioactive material (IL33-MAP) capable of stimulating macrophages in vitro via a ST-2 receptor dependent pathway and modulating immune cell recruitment to the implant site in vivo, which indicates an upregulation of a type 2-like immune response and downregulation of a type 1-like immune response.","journal":"Advanced Healthcare Materials","year":2024,"id":440179,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":9,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9632,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2024-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1115848,"name":"Samantha L. Lempke","orcid":null,"position":1,"is_corresponding":false},{"id":339140,"name":"Riley T. Hannan","orcid":"0000-0003-0403-792X","position":2,"is_corresponding":false},{"id":1251797,"name":"Ethan Nicklow","orcid":"0000-0003-1685-4919","position":3,"is_corresponding":false},{"id":59341,"name":"Jeffrey M. Sturek","orcid":"0000-0002-2731-3299","position":4,"is_corresponding":false},{"id":407050,"name":"Sarah E. Ewald","orcid":"0000-0002-5327-7578","position":5,"is_corresponding":false},{"id":227273,"name":"Donald R. Griffin","orcid":"0000-0002-3458-867X","position":6,"is_corresponding":false},{"id":742300,"name":"Colleen Roosa","orcid":"0000-0003-0824-1899","position":0,"is_corresponding":true}],"reference_count":57,"raw_metadata":null,"created_at":"2026-07-19T02:00:57.233748Z","pmid":"38648258","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}